mTOR Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer.

In this study, co-implantation of SC1 with U87MG cells ( Supplementary Figure S2 ) or intravenously treated U87MG tumor-bearing mice with suboptimal dose regimen of SC1 ( Figure 6A ) showed a clear trend for efficacy, although the tumor volume reduction did not reach statistical significance.

also in 19,460 other papers